Brahim Tighilet is a lecturer and researcher at Aix Marseille University, working at the Centre de Recherche en Psychologie et Neuroscience (CRPN UMR 7077 - AMU & CNRS). He is head of the ‘VESTIMED’ physiology and therapy of vestibular disorders team. His research focuses on the pathophysiology of vestibular disorders. The main aim of his work is to improve our understanding of the endogenous neuroplasticity mechanisms responsible both for the expression of vestibular pathology and for those involved in the recovery of balance function after vestibular damage. His most original recent discovery concerns the first evidence of post-injury vestibular neurogenesis (birth of new neurons in the vestibular nuclei) in an experimental model of vestibular pathology and its beneficial role in restoring static and dynamic balance functions. Over the last few years, he has developed an ongoing partnership with the pharmaceutical industry in the field of the neuropharmacology of vertigo. In particular, his work has enabled him to demonstrate for the first time the mechanisms and sites of action of betahistine (Tighilet et al., 2002) and the active principle of Tanganil (Tighilet et al., 2015). All his work has made him a recognised expert in the field of vestibular compensation and the pharmacology of vertigo. He has given many seminars and invited lectures, as well as numerous papers at international and national congresses. He has published over 70 articles in various scientific journals and book chapters. He co-founded a start-up company to promote his academic work. This led to the filing of patents with the CNRS for pharmacological compounds to combat vertigo.